The Pennsylvania-based drug distributor announced it would be buying OneOncology, a physician-led specialty service group in which it already owned a minority stake. The company said the acquisition will complement its "pharmaceutical-centric strategy." 

The new guidance, published in JACC, focuses on three classes of commonly used anticancer therapies.

Leaders from both companies are optimistic about how their partnership can improve precision medicine and palliative therapies. 

The use of artificial intelligence has the potential to significantly improve the diagnosis of pancreatic cancer, new data suggest. 

The positive findings come after the U.S. Food and Drug Administration previously shared concerns related to sterility assurance issues during the drug’s production.